Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Common Equity (2020 - 2025)

Maravai Lifesciences Holdings has reported Common Equity over the past 6 years, most recently at $212.4 million for Q4 2025.

  • Quarterly results put Common Equity at $212.4 million for Q4 2025, down 34.71% from a year ago — trailing twelve months through Dec 2025 was $212.4 million (down 34.71% YoY), and the annual figure for FY2025 was $212.4 million, down 34.71%.
  • Common Equity for Q4 2025 was $212.4 million at Maravai Lifesciences Holdings, down from $431.9 million in the prior quarter.
  • Over the last five years, Common Equity for MRVI hit a ceiling of $905.2 million in Q4 2022 and a floor of $212.4 million in Q4 2025.
  • Median Common Equity over the past 5 years was $633.5 million (2022), compared with a mean of $617.0 million.
  • Biggest five-year swings in Common Equity: soared 252.42% in 2021 and later tumbled 58.82% in 2024.
  • Maravai Lifesciences Holdings' Common Equity stood at $545.4 million in 2021, then soared by 65.99% to $905.2 million in 2022, then decreased by 12.74% to $789.9 million in 2023, then plummeted by 58.82% to $325.3 million in 2024, then tumbled by 34.71% to $212.4 million in 2025.
  • The last three reported values for Common Equity were $212.4 million (Q4 2025), $431.9 million (Q3 2025), and $468.0 million (Q2 2025) per Business Quant data.